Table 1:
Patient demographic and clinical characteristics at enrolment
| Total (n=206) | HIV-Infected (n=150) | HIV-Uninfected (n=56) | P-Value | |
|---|---|---|---|---|
| Median age, years (IQR) | 33 (26-41) | 34 (28-40) | 27 (21-48) | 0.91 |
| Female | 131 (64) | 105 (70) | 26 (46) | <0.01 |
| Weight (Baseline), kg (IQR) | 55 (48-62) | 54 (47-61) | 56 (50-63) | 0.74 |
| Race, n (%) | 0.07 | |||
| Black | 204 (99) | 150 (100) | 54 (96) | |
| Indian | 1 (0.5) | 0 | 1 (2) | |
| White | 1 (0.5) | 0 | 1 (2) | |
| Previous treatment for TB, n (%) | 133 (65) | 107 (71) | 26 (46) | <0.01 |
| Outcome of most recent TB episode, n (%) | 0.29 | |||
| Cure/Complete | 94 (71) | 78 (73) | 16 (62) | |
| Failure | 28 (21) | 19 (18) | 9 (35) | |
| Interruption/Loss to follow-up | 8 (6) | 7 (7) | 1 (4) | |
| Unknown | 3 (2) | 3 (3) | 0 (0) | |
| Smoking, n (%) | 47 (23) | 35 (23) | 12 (21) | 0.77 |
| Alcohol use, n (%) | 63 (31) | 49 (33) | 14 (25) | 0.29 |
| Receiving Antiretroviral therapy (ART) at MDR-TB treatment initiation, n (%) | -- | 121 (81) | N/A | |
| Duration on ART at MDR-TB treatment initiation, median months (IQR) | -- | 9 (3-30) | N/A | |
| CD4 count at MDR-TB treatment initiation, median cells/mm3 (IQR) (n=144) | -- | 215 (114-378) | N/A | |
| Viral load <150 copies/ml at MDR-TB treatment initiation (n=86) | -- | 52 (60) | N/A | |
| Sputum smear status positive (n=154)a | 76 (49) | 57 (49) | 19 (51) | 0.78 |
| Baseline chest radiograph (n=204) | ||||
| Cavitary disease | 95 (47) | 71 (47) | 24 (44) | 0.72 |
| Bilateral disease | 122 (60) | 81 (54) | 41 (76) | <0.01 |
a
Sputum smear was available for 117 HIV-infected and 37 HIV-uninfected patients; N/A: Not Applicable; Bold indicates statistical significance.